{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:24:50Z","timestamp":1787635490468,"version":"build-2736575974"},"reference-count":0,"publisher":"Clujul Medical","issue":"4","license":[{"start":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T00:00:00Z","timestamp":1649808000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicine and Pharmacy Reports"],"abstract":"<jats:p>SARS-CoV-2 associated liver injury: a six-month follow-up analysis of liver function recovery\r\n\u00a0\r\n\u00a0\r\nBackground and aims. SARS-CoV-2 infection has raised the interest in clinical and paraclinical research worldwide, representing a public health issue since the beginning of 2020. Studies have established the variable, unpredictable character of COVID-19. Our main objective was to assess the liver function of patients without pre-existing liver disease, diagnosed with SARS-CoV-2 associated liver injury in a 6-month follow-up study after discharge.\r\nMethods. We conducted a prospective paraclinical and imagistic follow-up study between 1st September 2020 and 30th April 2021 on patients without pre-existing liver disease previously diagnosed with SARS-CoV-2 associated liver injury who had been admitted in Mures County Clinical Hospital, Targu Mures, Romania. We followed up patients \u2019clinical and paraclinical characteristics at index COVID-19 hospitalization and at T1 (6-month follow-up visit).\r\nResults. We performed abdominal ultrasonography and laboratory examinations in 78 patients (mean age 45\u00b110 years) hospitalized 6 months earlier for symptomatic COVID-19, with a male:female ratio of 1.3:1.\r\nThirty patients (38.46%) were discharged at index COVID-19 hospitalization with abnormal liver function tests, while the rest presented paraclinical normalization at discharge and mean duration of liver injury of approximately 7 days. Follow-up examination revealed abnormal liver function tests in twenty-four patients, most of which presented with mild liver injury. All patients with severe COVID-19 at index hospitalization present with abnormal liver function tests at follow-up examination.\r\nConclusions. By performing a complete clinical and paraclinical 6-month follow-up study, with a specific focus on 34.6% of patients in which we noted a persistence of liver function tests abnormality, we could analyse a possible long-term effect of SARS-CoV-2 infection over liver function and also raise awareness of liver function tests monitoring and therapeutic management in post COVID-19 patients. Long-term follow-up studies of COVID-19 multi-organ sequelae are therefore mandatory in order to improve the practice of consultant gastroenterologists.<\/jats:p>","DOI":"10.15386\/mpr-2347","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T20:01:02Z","timestamp":1649880062000},"page":"393-399","source":"Crossref","is-referenced-by-count":2,"title":["SARS-CoV-2 associated liver injury: a six-month follow-up analysis of liver function recovery"],"prefix":"10.15386","volume":"95","author":[{"given":"Adina","family":"Roman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Septimiu","family":"Moldovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mircea","family":"Stoian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brindusa","family":"Tilea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Dobru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6100","published-online":{"date-parts":[[2022,4,13]]},"container-title":["Medicine and Pharmacy Reports"],"original-title":[],"link":[{"URL":"https:\/\/medpharmareports.com\/index.php\/mpr\/article\/download\/2347\/2968","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medpharmareports.com\/index.php\/mpr\/article\/download\/2347\/2968","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T15:51:04Z","timestamp":1750780264000},"score":1,"resource":{"primary":{"URL":"https:\/\/medpharmareports.com\/index.php\/mpr\/article\/view\/2347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,13]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,10,28]]}},"URL":"https:\/\/doi.org\/10.15386\/mpr-2347","relation":{},"ISSN":["2668-0572","2602-0807"],"issn-type":[{"value":"2668-0572","type":"electronic"},{"value":"2602-0807","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,13]]}}}